Study Design. A consecutive retrospective cohort study from 2008 to 2013 at a single tertiary-care institution was conducted.
V ertebral osteomyelitis (VO) is characterized by an acute or recurrent infection of the spine and the subsequent inflammatory destruction of bone. 1, 2 Patients with diabetes, renal failure, infective endocarditis, immunosuppressive disorders, and intravenous drug abuse are at elevated risk for this disease. [3] [4] [5] [6] Antibiotics are first-line therapy, generally yielding favorable outcomes; however, in cases of neurologic compromise, hospital-acquired infection, or delayed diagnosis, medical therapy may fail, necessitating surgery in a minority of patients (10%-40%). [7] [8] [9] [10] [11] Unfortunately, studies regarding surgical outcomes have been limited, instead focusing on technique, indications, and timing. [12] [13] [14] [15] [16] [17] [18] Surgical intervention carries risks and financial costs; however, forgoing surgery when indicated may result in permanent neurologic deficit or death. Although prior studies have reported the natural history, risk factors, indications, and mortality after surgical management, the associated reoperation rate, pain, and neurologic recovery after surgery 
MATERIALS AND METHODS

Patient Selection
A consecutive retrospective cohort study of all individuals with diagnoses of VO between January 2008 and December 2013 at a single tertiary-care institution was conducted. Inclusion criteria were diagnosis and surgery for VO, as well as radiologic (via x-ray/magnetic resonance imaging) or microbial (blood/surgical cultures) evidence of osteomyelitis. Exclusion criteria were patients with a prior history of surgical intervention for VO and age less than 18 years.
Data Collection
Demographic, symptomatic, comorbid, radiologic, operative, and postoperative data were collected in a retrospective fashion from electronic medical records. Patients with active malignancy, long-term steroid use, immunosuppressive therapy, organ transplants, and HIV infection were considered immunocompromised.
A Modified McCormick Scale (MMS) and pain Visual Analog Scale (VAS) were collected throughout the patient's clinical course as measures of neurologic status and degree of pain, respectively. The MMS is a measure of ambulatory capacity and neurologic deficit (1 ¼ neurologically intact, normal ambulation; 2 ¼ mild motor/sensory deficit, functional independence; 3 ¼ moderate deficit, limitation of function, independent with external aid; 4 ¼ severe motor or sensory deficit, limited function, dependent; 5 ¼ paraplegia or quadriplegia). 20, 21 The VAS measures pain (0 cm ¼ no pain, 10 cm ¼ worst pain imaginable). 22, 23 Medical and surgical treatment data were collected from presentation to last follow-up (or death), including reoperations and the use of multiple antibiotics. Intraoperative and short-term postoperative (<30 d) complications were collected. Long-term neurologic deficits and complications were likewise identified. A neurologic complication was considered to be a new-onset neurologic deficit in the postoperative period, including upper extremity or lower extremity weakness or numbness, as well as fecal or urinary incontinence. The primary outcome variable was change from baseline in MMS, whereas secondary outcome variables included change from baseline in VAS and reoperation.
Statistical Analyses
Data were analyzed using the JMP Pro 10 statistical software (SAS Institute Inc., Carey, NC; 2012). 24 The Student t test was used to analyze continuous variables, whereas the Fisher exact test was used to analyze categorical variables. The Mann-Whitney U test was used for detecting longitudinal differences in MMS and VAS. Both simple-and multivariable linear and logistic regression were performed to identify predictors of primary and secondary outcomes variables. Change in MMS and VAS from baseline was normalized to their respective preoperative scores to account for ceiling effect. Only covariates associated (P < 0.20) with outcome variables on simple regression were included in multivariable models to avoid over-fitting. All covariates were tested for collinearity (R 2 ! 0.80); P value less than 0.05 was considered statistically significant.
RESULTS
Preoperative and Treatment Data
A total of 360 patients were diagnosed with VO within the study period; of these, 310 (86%) were managed conservatively, whereas 50 (14%) were managed surgically. These 50 patients were included in the present investigation (Table 1) , with a mean age of 60, body mass index of 28, and male predominance (66%). Among the 6 (12%) immunocompromised patients, 3 had active malignancy. These malignancies included hepatocellular carcinoma diagnosed 3 months preoperatively, malignant ependymoma diagnosed 1 month preoperatively, and ovarian cancer diagnosed 6 months preoperatively. In addition, 2 patients had undergone renal transplant and were on chronic immunosuppression: 1 patient had been on tacrolimus alone for 8 years, whereas the second had been on prednisone, tacrolimus, and mycophenolate for 3 years. Finally, 1 patient had been taking prednisone and intermittent intravenous immunoglobulins for 6 months preoperatively for an inflammatory neuropathy. More than half of patients suffered from an epidural abscess (54%) or discitis (64%) in addition to osteomyelitis. Fever was present in 28% of the population at presentation, whereas 52% presented with neurologic deficits. The mean preoperative MMS was 2.74, and the preoperative VAS was 6.40. Leukocytosis was uncommon at presentation; however, the mean ESR and CRP were elevated. Blood and surgical site cultures were positive in 39 (78%) patients.
All patients received at least one antibiotic during the course of their therapy ( Table 2 ). The mean number of operative vertebral levels was 3. The distribution of operative levels and location of epidural abscesses is shown in Figure 1 .
Short-Term (<30 d) Postoperative Complications
Patients' mean length of stay was 11 days (Table 3) . Fortyeight percent of patients experienced a short-term postoperative complication; wound infection and instrumentation failure were most common. One patient died within 30 days of the index operation. Twenty-six percent of patients required reoperation.
Long-Term Outcome Variables
Longitudinal data regarding surgical outcomes (VAS, MMS, and neurologic deficits/complications) are shown in Table 4 . The median length of follow-up was 18 months. A statistically significant improvement from baseline MMS was observed at postoperative months 12 and 24, whereas a statistically significant improvement from baseline VAS was observed at postoperative months 3, 6, 12, and 24. At last follow-up, 32 (64%) patients experienced improvement in VAS, whereas 6 (12%) worsened. The mean improvement in MMS at last follow-up was 0.35 AE 0.91, whereas the mean improvement in VAS was 3.40 AE 3.86. Preoperatively, 26 patients (52%) presented with a neurologic deficit. At 6 months postoperatively, 7 patients (15%) suffered a new neurologic deficit, whereas 6 (12%) had residual deficits. At last follow-up, 27 patients (54%) had no change in MMS, 17 (34%) improved, and 6 (12%) worsened.
The progression of death, reoperation, and neurologic complications is shown in Figure 2 . At 24 months postoperatively, 10% of patients had died, 26% had underwent reoperation, 42% had experienced a neurologic complication, and 60% had experienced at least one of these 3 adverse events. Among the 10% of patients who died, the causes of death were disseminated intravascular coagulation secondary to sepsis, sepsis as a complication of paraplegia, myocardial infarction, hepatocellular carcinoma, and pancreatic carcinoma (diagnosed 3 mo postoperatively).
Regression Analysis
Simple regression revealed 4 variables associated (P < 0.20) with change in MMS: sex, immunocompromised state, discitis, and number of operative levels. After controlling for confounders with multivariable regression modeling, immunocompromised state (b ¼ 0.42, P ¼ 0.02) and increased number of operative levels (b ¼ 0.12, P ¼ 0.04) remained significantly predictive of diminished MMS improvement (Table 5 ).
Variables associated (P < 0.20) with change in VAS included age, end-stage renal disease, and duration of symptoms before surgery. After controlling for confounders with multivariable regression modeling, only longer duration of symptoms preoperatively (b ¼ 0.01, P ¼ 0.04) remained significantly independently predictive.
Variables associated (P < 0.20) with reoperation included history of smoking, coronary artery disease, and longer hospital stay. After controlling for confounders, only longer hospital stay (odds ratio ¼ 1.11, P ¼ 0.04) remained significantly predictive.
DISCUSSION
Two large national studies in Japan and Denmark have suggested that the incidence of VO is increasing, particularly in patients with immunocompromised health. 3 -5,8,25,26 This increasing incidence may be related to aging populations and longer life expectancies for patients with these comorbidities, as well as increasing pathogen resistance to antibiotics.
Although mortality and recurrence data are available for patients with VO, little data is available regarding postoperative morbidity and recovery of neurologic function. 5 We hypothesized that surgery provided clinical benefit to patients with VO, but that most patients would nevertheless experience a postoperative adverse event.
Clinical Outcomes
The primary outcome variable of the present study was recovery of neurologic and ambulatory status. MMS trended downward throughout the entire postoperative period (indicating a gradual recovery of neurological function). A statistically significant improvement was ultimately observed at 12 and 24 months postoperatively. This mean improvement was, however, relatively small (0.35 on MMS scale), and 54% of patients experienced no change in MMS, whereas only 34% improved. In contrast, the mean improvement in VAS was more robust and clinically significant (3.40). For VAS, a statistically significant improvement was first observed at 3 months postoperatively and continued to decrease. Moreover, 64% of patients experienced an improvement in VAS. These data support the overall benefit of surgical intervention with regard to recovery of neurologic function and alleviation of pain. Menon et al 17 investigated outcomes in 32 consecutive patients that underwent one-stage surgery for VO. Although there were no long-term neurological outcomes reported, the study concluded that all patients qualitatively returned to their preoperative mobility status. In the present study, although many patients (34%) improved, 12% worsened.
Mohamed et al 16 described outcomes in the treatment of 15 patients with VO via posterior decompression and stabilization. These authors reported a significant improvement in the number of patients ambulatory postoperatively (14, 93%) compared with preoperatively (6, 40%), with a reoperation rate of 20%. Change in neurologic function scores, specific neurologic deficits, and duration to reoperation was not reported. In the present study, 78% of patients were ambulatory (MMS I-III) at last follow-up, marginally improved from 68% preoperatively.
Adverse Events
By 24 months postoperatively, 19 patients (42% of living cohort) had experienced at least one neurologic complication; 17 of these 19 patients (89%) suffered this neurologic complication within 6 months postoperatively. The relative rarity of these complications at 12 and 24 months corresponds with the statistically significant improvement in MMS at months 12 and 24. These results suggest that the first 6 months postoperatively necessitate the greatest clinical attention. Such complications may result from incomplete infection clearance, iatrogenic injury during surgery, instrumentation failure, or degenerative changes secondary to infection.
Thirteen patients (26%) underwent reoperation in the present study; this rate is similar to that reported by Mohamed et al, who described reoperation in 3 of 15 (20%) patients undergoing surgery for VO. 16 This rate is slightly higher than published reoperation rates for various degenerative indications (15%-20%). 27, 28 This may suggest a role for earlier or more aggressive index surgery.
Overall, all-cause adverse events (death, neurologic complications, and reoperation) occurred in 60% of the population by 24 months postoperatively. This is likely related to the advanced stage of disease that qualifies a patient for surgery. Patients consented for these procedures should be informed of both the expected clinical improvement and the incidence of potential complications.
Predictors of Adverse Events
In the present study, multivariable linear and logistic analyses revealed several factors independently associated with our primary and secondary outcome variables. We found that immunocompromised patients experienced a This effect may be related to impaired healing in the postoperative period, or due to recurrence of infection and continued vertebral destruction. 14, [29] [30] [31] We also observed that each additional operative level carries an associated 0.12 unit diminished improvement in MMS, suggesting that more extensive index operations independently diminish neurologic improvement. This observation is partially supported by McHenry et al, 7 who reported that involvement of more than 2 vertebrae was a risk factor for recurrence after simple regression.
Multivariable regression revealed that each additional symptomatic day before index operation carries an associated 0.01 diminished improvement in VAS. As such, a patient with 6 weeks of symptoms before surgery may expect 0.5 less VAS improvement compared with a patient with only 1 week of symptoms before surgery. Although this effect is small, it is partially supported by Alton et al, who reported that early surgical intervention results in superior outcomes for patients with cervical epidural abscesses compared with medical failure and subsequent delayed surgery. 14, 15 These findings highlight the challenge in determining the optimal duration of conservative care before surgical intervention.
Previously reported predictors of poor outcome in VO have been limited, with little data available for patients undergoing surgery. 19, 29, 30 Akiyama et al conducted a retrospective review of 7118 patients in the Japanese national diagnosis procedure database. 5 Although 22% of patients underwent surgery, no subgroup analysis was performed for predictors of surgical outcome. Predictors of mortality included older age, hemodialysis use, diabetes, liver cirrhosis, malignancy, infective endocarditis, and hospitals with lower case volume.
McHenry et al 7 conducted a retrospective review of 253 American patients with VO. Surgery was performed in 43% of cases, but no specific surgical outcomes were reported. Multivariable regression identified patients with motor weakness, hospital-acquired infections, and longer preoperative duration (>2 mo) of symptoms at risk for poor improvement.
Treatment of patients with VO requires a thoughtful, collaborative approach of infectious disease specialists and spine surgeons. Clearly, in the case of structural and/or neurological demise, the importance of a successful initial surgery cannot be overstated.
Limitations
This was a retrospective study and as such was subject to the inherent limitations of any retrospective analysis, including bias, heterogeneity of data in the electronic medical record, and variable length and frequency of follow-up. Patients dying of osteomyelitis or other disease processes have truncated follow-up times, and thus reoperation rates and neurologic complications cannot be extrapolated in this subset of patients. Notably, the greatest degree of change in MMS and VAS occurred within 12 months postoperatively, as did the vast majority of neurologic complications. We acknowledge the limitation of MMS and VAS scores, as they are based on the examiner's assessment of ambulation and patient's self-reported degree of pain. Moreover, VAS scores are confounded by analgesic use. Nonetheless, these are validated assessment tools, which are available and convenient for assessing outcomes in the absence of prospectively collected measures.
Finally, the sample size was relatively small, which decreases the power of this study to detect less robust predictors that could be potentially identified with larger sample sizes. Certainly, the present results are subject to confounding from a variety of sources. In an attempt to address this, multivariable regression analysis was performed. Although all patients underwent surgical intervention for VO, there were 2 principal indications for surgical over conservative management. First, 52% of patients presented with acute neurologic deficit requiring immediate urgent intervention in an attempt to prevent permanent deficit. Second, 48% of patients had failed conservative therapy and required surgical intervention for clearance of the infected site.
This difference in indication for surgery may be a source of confounding as it relates to the present results. As such, all 3 multivariable regression models tested for association between preoperative neurologic status (MMS) and outcome variables as a surrogate for specific surgical indication. This was performed to determine if surgical intervention for neurologic deficit impacted clinical outcomes. Among the 3 models, only the first (recovery of neurologic function) identified preoperative MMS as a contributor to the model; moreover, this variable was included to account for the ceiling effect and is not necessarily indicative of future change in MMS. Beyond this consideration, variations in clinical judgment to operate certainly offer potential for confounding. Despite these limitations, this is the first study to report specific predictors of adverse outcomes after surgical intervention in VO.
CONCLUSION
The present study is the first to longitudinally detail neurological complications, pain, and reoperation after surgery for VO. In the present study, we found statistically significant improvements in neurologic status at 12 months postoperatively, and in pain at 3 months postoperatively.
Despite these improvements, the 24-month cumulative incidence of new-onset neurologic deficits in the postoperative period was high (42%), reoperation was common (26%), and the rate of overall adverse events was 60%. Risk factors for poor clinical outcome include immunocompromised state, increased number of operative levels, and greater preoperative duration of symptoms. Patients and clinicians should be aware of the postoperative improvement but high incidence of adverse events after surgery for VO.
Key Points
Surgical intervention for VO was observed to provide a clinical benefit with regard to long-term recovery of neurologic function, ambulation, and pain. Despite this long-term clinical improvement, reoperation, neurologic complications, and mortality are relatively common in the postoperative period, with 60% experiencing at least one of these events within 24 months. Certain patients were identified to be at greater risk for failure to achieve clinical improvement, including immunocompromised patients, those undergoing more extensive surgeries, and those with delayed surgical intervention after conservative therapy.
